Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on‐off‐on design

Hummel, Barbara; Walden, J.; Stampfer, Robert; Dittmann, Sandra; Amann, Benedikt L.; Sterr, Andrea; Schaefer, Martin; Frye, Mark A.; Grunze, Heinz

doi:10.1034/j.1399-5618.2002.02228.x

Cited by 48 publications

(30 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…60,61 In a small recent study, 4 of 12 consecutively admitted acutely manic patients with bipolar I or II disorder responded to oxcarbazepine 900 to 2100 mg/day with a reduction of their Young Mania Rating Scale score by 50% or more from baseline. 62 Oxcarbazepine was administered as add-on therapy to 16 patients with bipolar I or II disorder who were experiencing mania, depression, or a mixed episode despite ongoing lithium therapy. At the end of the eight-week trial, 11 of the patients had achieved a response, defined as a CGIbipolar disorder (CGI-BD) improvement section score of 2 or 1 (much or very much improved).…”

Section: Oxcarbazepinementioning

confidence: 99%

Use of Antiepileptic Drugs for Nonepileptic Conditions: Psychiatric Disorders and Chronic Pain

2007

View full text Add to dashboard Cite

Summary: Antiepileptic drugs (AEDs) are commonly utilized for nonepileptic conditions, including various psychiatric disorders and pain syndromes. Evidence for their benefit in these nonepileptic conditions varies widely among different drugs, but there is, in general, a paucity of published multicenter randomized double-blind trials. Variable levels of evidence suggest that lamotrigine and the vagal nerve stimulator have antidepressant properties. Carbamazepine, valproate, lamotrigine, and oxcarbazepine appear to have mood stabilizing properties while gabapentin, pregabalin, and tiagabine have anxiolytic benefits. Barbiturates, topiramate, and possibly phenytoin may precipitate or exacerbate depression. Underlying depression and anxiety symptoms may be exacerbated by levetiracetam, while psychotic symptoms have rarely been reported with topiramate, levetiracetam, and zonisamide. Pregabalin, gabapentin, carbamazepine, and oxcarbazepine have been used to treat neuropathic pain such as postherpetic neuralgia, and diabetic polyneuropathy. Topiramate and divalproex sodium have utility in the prophylaxis or acute treatment of migraine. Further rigorous studies are needed to clarify the utility of AEDs in nonepileptic conditions.

show abstract

Section: Oxcarbazepinementioning

confidence: 99%

Use of Antiepileptic Drugs for Nonepileptic Conditions: Psychiatric Disorders and Chronic Pain

2007

View full text Add to dashboard Cite

show abstract

“…Hummel and others conducted an open trial with a nonrandom on-off-on design to examine the efficacy of OXC in 12 patients with mild to moderate mania (31). All patients were treated for 14 days with OXC as monotherapy.…”

Section: Open-label Monotherapy Studies (Class B)mentioning

confidence: 99%

“…Hummel and others found that 1 of 12 patients (8%) gained weight (31), and another study found that 8 of 18 psychiatric patients (44%) gained weight (30). One chart review found that 2 of 13 patients with BD (15%) gained weight (20).…”

Section: Weightmentioning

confidence: 99%

See 1 more Smart Citation

Oxcarbazepine in the Treatment of Bipolar Disorder: A Review

et al. 2006

View full text Add to dashboard Cite

A lthough lithium is considered the gold standard of treatment for BD, research and clinical experience over the past 4 decades have indicated that only a small proportion of patients with BD remain episode-or symptom-free using lithium monotherapy in long-term maintenance treatment (1,2). Thus, to improve outcomes for a substantial number of patients with BD, anticonvulsants and atypical antipsychotics are often used as alternatives or augmentation strategies to lithium. Among anticonvulsants, VPA and CBZ have proven efficacy in treating acute mania (3), and they are likely effective in maintenance treatment, although well-designed double-blind, placebo-controlled trials supporting their

show abstract

“…There was recently an increased interest in its potential role as a thymoleptic agent. Because of its favorable side effect profile, it appeared to be a potentially attractive option in the acute monotherapy for mixed and manic states (Hummel et al 2002).…”

Section: Oxcarbazepinementioning

confidence: 99%

Psychopharmacology of pediatric bipolar disorder: a review

Smarty

Findling

2006

Psychopharmacology

View full text Add to dashboard Cite

show abstract

Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on‐off‐on design

Abstract: Antimanic activity of OXC was demonstrated in this pilot study only for patients with mild or moderate manic symptoms. Further studies are encouraged to clarify OXC's role as mood-stabilizer and assess whether it has a profile similar to that of carbamazepine.

Cited by 48 publications

References 24 publications

Use of Antiepileptic Drugs for Nonepileptic Conditions: Psychiatric Disorders and Chronic Pain

Use of Antiepileptic Drugs for Nonepileptic Conditions: Psychiatric Disorders and Chronic Pain

Oxcarbazepine in the Treatment of Bipolar Disorder: A Review

Psychopharmacology of pediatric bipolar disorder: a review

Contact Info

Product

Resources

About